Clopidogrel Bisulfate
Product Images NDC 67296-1869

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 67296-1869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01)

FDA Label Image

Fig 1 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02)

This information appears to be related to the co-administration of different proton pump inhibitors (PPIs) with the dosages mentioned and their effects on the active metabolite. The text provides data on mean and 90% confidence interval with a comparison to clopidogrel tablets administered alone. It suggests a comparison of the impact of these PPIs at the specified dosages on the active metabolite AUC.*

FDA Label Image

Fig 2 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03)

This text is not readable.*

FDA Label Image

Fig 3 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04)

This is a tabular representation showing the distribution and comparison of different variables within subgroups based on age, gender, race, and medical conditions such as diabetes, previous heart attack, and stroke. The table also includes the number and percentages of participants receiving Clopidogrel and Placebo in each subgroup. The last section mentions hazard ratios with 95% confidence intervals for the comparison between Clopidogrel and Placebo.*

FDA Label Image

Fig3-a (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05)

This text provides a table showing data related to different subgroups and their responses to various medications like Heparin/LMWH, Aspirin, GPIIb/IIIa Antag, Beta-Blocker, and Ace Inhibitor. Additionally, it shows the overall results of Clopidogrel and Placebo treatments, including the number and percentage of patients in each group. The table also includes a comparison between the two treatments in terms of favorability and hazard ratio with a 95% confidence interval.*

FDA Label Image

Fig 4 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06)

This is a comparative analysis between placebo and clopidogrel in terms of the percentage of deaths and proportional risk reduction over a period of up to 28 days after randomization. All treated patients received aspirin as part of the study. The data suggests that clopidogrel might have a beneficial impact, as indicated by a reduction in deaths and a statistically significant p-value of 0.03.*

FDA Label Image

Fig 5 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07)

This text appears to be a comparison of the Placebo group and the Clopidogrel group in a clinical trial, showing event rates and a significant risk reduction percentage. The analysis covers outcomes such as death, reinfarction, or stroke leading up to the first discharge. The data is presented for a period of up to 28 days since randomization, with the note that all treated patients received aspirin. This information can be useful for evaluating the effectiveness of Clopidogrel compared to Placebo in reducing risks of adverse events in patients.*

FDA Label Image

Fig 6 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08)

This text appears to be a statistical table showing subgroup analysis of participants receiving Clopidogrel versus Placebo across different variables like gender, age, hours since onset, SBP, heart rate, and fibrinolytic agent given. It evaluates the odds ratio with a 95% confidence interval. The table highlights the number and percentage of individuals favoring Clopidogrel versus Placebo in each subgroup.*

FDA Label Image

Fig 8 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09)

This is a tabular representation of the cumulative event rate (%) for fatal or non-fatal vascular events over a follow-up period of 24 months with the medication Clopidogrel bisulfate. The event rates at 3, 12, 18, and 24 months are displayed.*

FDA Label Image

Fig 5 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10)

This is a statistical table comparing the use of Clopidogrel and Aspirin in patients with different qualifying conditions such as Stroke, MI (Myocardial Infarction), and PAD (Peripheral Arterial Disease). The table shows the number of patients in each group, the percentage of patients using each medication, and the Hazard Ratio for each condition. The data indicates that Clopidogrel may be more favorable than Aspirin for certain conditions based on the Hazard Ratio values.*

FDA Label Image

Fig6 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 11)

FDA Label Image

1 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 12)

FDA Label Image

Label (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 13)

This text describes a medication containing 75 mg of clopidogrel, with a total weight of 9575 g, packaged in blister packs with 30 tablets per package. The medication is for prescription use only and should be stored at room temperature. Pharmacists should review the accompanying prescribing information before dispensing this medicine.*

FDA Label Image

75mg- Dahej (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 14)

Each tablet of Clopidogrel contains 97.875 mg of clopidogrel bisulfate, equivalent to 75 mg of clopidogrel. It is recommended to store between 20° to 25°C (68° to 77°F) with excursions allowed between 15 to 30°C (59° to 86°F). The medication should be dispensed in a tight container with a child-resistant closure. Pharmacists should provide the accompanying Medication Guide to each patient. The usual dosage is specified in the prescribing information. This medication is manufactured by Torrent Pharmaceuticals Ltd. in India and distributed by Torrent Pharma Inc. in Basking Ridge, NJ.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.